BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Inotek Pharmaceuticals Corporation to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11


3/4/2010 10:51:37 AM

LEXINGTON, MA--(Marketwire - March 04, 2010) -

Inotek Pharmaceuticals Corp., a clinical-stage drug development company advancing innovative drug candidates to address significant eye disease, with a major focus on glaucoma, today announced that Paul G. Howes, President and CEO, will present a corporate overview at the Cowen and Company 30th Annual Health Care Conference on Thursday March 11, 2010 at 9:30 a.m. Eastern Time. The conference will be held at the Boston Marriott Copley Place Hotel, Boston, MA.

About Inotek
Inotek is a privately-held, clinical-stage drug development company advancing innovative drug candidates to address significant eye disease, with a major focus on glaucoma. Inotek's lead drug candidate INO-8875 is a potential first-in-class treatment for glaucoma and ocular hypertension that significantly reduced intraocular pressure (IOP) in glaucoma subjects following single ocular doses in a Phase 1/2 clinical trial. The Company believes INO-8875 will be a breakthrough treatment that can be used alone or combined with other IOP-lowering medicines because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy elderly eyes to maintain normal IOP. The Company is also advancing a broad pipeline of PARP inhibitors and SOD mimetics that alleviate oxidative injury and inflammation, which it believes may address significant unmet medical needs in diseases of the back of the eye, or retina, such as the dry form of age-related macular degeneration (dry AMD). The Company is located in Lexington, MA. For further information on Inotek, please visit www.inotekcorp.com.


Company Information:
Adam L. Muzikant, Ph.D.
Senior Director, Business Development
Inotek Pharmaceuticals
(781) 676-2100

Media Relations:
Sarah Cavanaugh
MacDougall Biomedical Communications
Email Contact
(781) 235-3060

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES